Many biologic treatments are available for controlling symptoms of psoriasis. The treatments have varying purchase costs, dosing amounts and frequency, and real-world use. Therefore, understanding the total costs of these treatments to insurers can be difficult. A study recently published in PharmacoEconomics - Open considered these factors and the expected uptake of tildrakizumab to project the impact of introducing the drug on insurers’ budgets.
The study’s lead researcher Justin Carrico, Senior Research Health Economist with RTI Health Solutions, shares, “To our knowledge, this is the first study to consider the impact of tildrakizumab on health plan costs. Results showed that treatment acquisition prices were the largest driver of overall health plan costs for psoriasis treatment. Additional factors such as cost-sharing, drug rebates and discounts, and future introduction of biosimilars are likely to impact treatment costs in a real-world setting.”
Researchers modeled estimated costs based on published literature, clinical trials, and prescription data. Results suggest that tildrakizumab may reduce the cost of treating patients. “This research has the potential to better inform health-plan decision-makers on the total costs of biologic treatments for plaque psoriasis,” said Carrico.
The Budget Impact of Introducing Tildrakizumab to a United States Health Plan for Managing Moderate-to-Severe Plaque Psoriasis. Justin Carrico, Yang Zhao, Xiaoying Jia, Thor-Henrik Brodtkorb, Alan Mendelsohn, Simon Lowry (2020) https://doi.org/10.1007/s41669-020-00208-9